S&P 500   4,614.38 (+1.04%)
DOW   34,689.91 (+0.60%)
QQQ   397.29 (+0.88%)
AAPL   166.23 (+0.56%)
MSFT   335.02 (+1.34%)
FB   327.21 (+0.85%)
GOOGL   2,865.04 (+0.95%)
AMZN   3,535.00 (+0.80%)
TSLA   1,164.78 (+1.75%)
NVDA   329.77 (+0.92%)
BABA   127.74 (+0.16%)
NIO   40.44 (+3.35%)
CGC   10.79 (+0.75%)
AMD   159.63 (+0.80%)
GE   96.39 (+1.47%)
MU   86.40 (+2.86%)
T   23.01 (+0.79%)
F   19.60 (+2.14%)
DIS   146.50 (+1.10%)
ACB   6.44 (+0.31%)
PFE   53.11 (-1.15%)
AMC   34.86 (+2.71%)
BA   200.50 (+1.34%)
S&P 500   4,614.38 (+1.04%)
DOW   34,689.91 (+0.60%)
QQQ   397.29 (+0.88%)
AAPL   166.23 (+0.56%)
MSFT   335.02 (+1.34%)
FB   327.21 (+0.85%)
GOOGL   2,865.04 (+0.95%)
AMZN   3,535.00 (+0.80%)
TSLA   1,164.78 (+1.75%)
NVDA   329.77 (+0.92%)
BABA   127.74 (+0.16%)
NIO   40.44 (+3.35%)
CGC   10.79 (+0.75%)
AMD   159.63 (+0.80%)
GE   96.39 (+1.47%)
MU   86.40 (+2.86%)
T   23.01 (+0.79%)
F   19.60 (+2.14%)
DIS   146.50 (+1.10%)
ACB   6.44 (+0.31%)
PFE   53.11 (-1.15%)
AMC   34.86 (+2.71%)
BA   200.50 (+1.34%)
S&P 500   4,614.38 (+1.04%)
DOW   34,689.91 (+0.60%)
QQQ   397.29 (+0.88%)
AAPL   166.23 (+0.56%)
MSFT   335.02 (+1.34%)
FB   327.21 (+0.85%)
GOOGL   2,865.04 (+0.95%)
AMZN   3,535.00 (+0.80%)
TSLA   1,164.78 (+1.75%)
NVDA   329.77 (+0.92%)
BABA   127.74 (+0.16%)
NIO   40.44 (+3.35%)
CGC   10.79 (+0.75%)
AMD   159.63 (+0.80%)
GE   96.39 (+1.47%)
MU   86.40 (+2.86%)
T   23.01 (+0.79%)
F   19.60 (+2.14%)
DIS   146.50 (+1.10%)
ACB   6.44 (+0.31%)
PFE   53.11 (-1.15%)
AMC   34.86 (+2.71%)
BA   200.50 (+1.34%)
S&P 500   4,614.38 (+1.04%)
DOW   34,689.91 (+0.60%)
QQQ   397.29 (+0.88%)
AAPL   166.23 (+0.56%)
MSFT   335.02 (+1.34%)
FB   327.21 (+0.85%)
GOOGL   2,865.04 (+0.95%)
AMZN   3,535.00 (+0.80%)
TSLA   1,164.78 (+1.75%)
NVDA   329.77 (+0.92%)
BABA   127.74 (+0.16%)
NIO   40.44 (+3.35%)
CGC   10.79 (+0.75%)
AMD   159.63 (+0.80%)
GE   96.39 (+1.47%)
MU   86.40 (+2.86%)
T   23.01 (+0.79%)
F   19.60 (+2.14%)
DIS   146.50 (+1.10%)
ACB   6.44 (+0.31%)
PFE   53.11 (-1.15%)
AMC   34.86 (+2.71%)
BA   200.50 (+1.34%)
NASDAQ:PACB

Pacific Biosciences of California Stock Forecast, Price & News

$23.35
+0.14 (+0.60%)
(As of 12/1/2021 09:34 AM ET)
Add
Compare
Today's Range
$22.91
$23.43
50-Day Range
$22.68
$30.08
52-Week Range
$15.19
$53.69
Volume
2,264 shs
Average Volume
2.97 million shs
Market Capitalization
$5.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.1
30 days | 90 days | 365 days | Advanced Chart
Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.


Pacific Biosciences of California logo

About Pacific Biosciences of California

Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. The firm's products and services include PacBio sequel system, consumables, analytical software and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.

Headlines

Pacific Biosciences of California (NASDAQ:PACB) Trading Down 5.7%
November 22, 2021 |  americanbankingnews.com
PacBio Grants Equity Incentive Award to New Employee
November 19, 2021 |  finance.yahoo.com
PacBio to Present at Upcoming Investor Conferences
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
412
Year Founded
2004

Sales & Book Value

Annual Sales
$78.89 million
Book Value
$3.81 per share

Profitability

Net Income
$29.40 million
Pretax Margin
-108.35%

Debt

Price-To-Earnings

Miscellaneous

Free Float
212,436,000
Market Cap
$5.15 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/09/2022

Social Links


MarketRank

Overall MarketRank

2.13 out of 5 stars

Medical Sector

441st out of 1,390 stocks

Analytical Instruments Industry

11th out of 33 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

Is Pacific Biosciences of California a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Pacific Biosciences of California stock.
View analyst ratings for Pacific Biosciences of California
or view top-rated stocks.

How has Pacific Biosciences of California's stock been impacted by COVID-19 (Coronavirus)?

Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PACB shares have increased by 581.1% and is now trading at $23.43.
View which stocks have been most impacted by COVID-19
.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Pacific Biosciences of California
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.01. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 29.42% and a negative net margin of 30.39%. During the same quarter last year, the company earned ($0.14) earnings per share.
View Pacific Biosciences of California's earnings history
.

What price target have analysts set for PACB?

4 brokers have issued 12-month target prices for Pacific Biosciences of California's stock. Their forecasts range from $41.00 to $62.00. On average, they expect Pacific Biosciences of California's share price to reach $50.00 in the next year. This suggests a possible upside of 113.4% from the stock's current price.
View analysts' price targets for Pacific Biosciences of California
or view top-rated stocks among Wall Street analysts.

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the following people:
  • Christian O. Henry, President, Chief Executive Officer & Director
  • Mark David van Oene, Chief Operating Officer
  • Susan G. Kim, Chief Financial Officer (LinkedIn Profile)
  • Stephen W. Turner, Chief Technology Officer
  • Jonas Korlach, Chief Scientific Officer

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California CEO Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among Pacific Biosciences of California's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.10%), Sumitomo Mitsui Trust Holdings Inc. (4.69%), Nikko Asset Management Americas Inc. (4.69%), SB Management Ltd (3.70%), Casdin Capital LLC (3.62%) and William Blair Investment Management LLC (2.06%). Company insiders that own Pacific Biosciences of California stock include Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends for Pacific Biosciences of California
.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including SB Management Ltd, Two Sigma Investments LP, Renaissance Technologies LLC, Millennium Management LLC, Goldman Sachs Group Inc., Eagle Asset Management Inc., Cambridge Investment Research Advisors Inc., and Caption Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include Eric Schaefer, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Susan G Kim, and William W Ericson.
View insider buying and selling activity for Pacific Biosciences of California
or view top insider-selling stocks.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was bought by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Casdin Capital LLC, Farallon Capital Management LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Pura Vida Investments LLC, Morgan Stanley, and Squarepoint Ops LLC.
View insider buying and selling activity for Pacific Biosciences of California
or or view top insider-buying stocks.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $23.43.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California has a market capitalization of $5.17 billion and generates $78.89 million in revenue each year. The biotechnology company earns $29.40 million in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

Pacific Biosciences of California employs 412 workers across the globe.

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

What is Pacific Biosciences of California's official website?

The official website for Pacific Biosciences of California is www.pacb.com.

Where are Pacific Biosciences of California's headquarters?

Pacific Biosciences of California is headquartered at 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at (650) 521-8000, via email at [email protected], or via fax at 302-636-5454.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.